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Abstract
Purpose To explore the value of gadolinium-enhanced MRI combined with diffusion-weighted MRI (Gd-enhanced MRI
with DWI) in addition to contrast-enhanced CT (CECT) for detection of synchronous liver metastases for potentially
resectable pancreatic cancer.
Methods By means of a retrospective cohort study we included patients with potentially resectable pancreatic cancer on
CECT, who underwent Gd-enhanced MRI with DWI between January 2012 and December 2016. A single observer
evaluated MRI and CT and was blinded to imaging, pathology, and surgery reports. Liver lesions were scored in both
modalities, using a 3-point scale: 1-benign, 2-indeterminate, 3- malignant (i.e., metastasis). The primary outcome
parameters were the presence of liver metastases on Gd-enhanced MRI with DWI and the sensitivity of Gd-enhanced MRI
with DWI for synchronous liver metastases.
Results We included 66 patients (42 men, 24 women; median age 65 years, range 36–82 years). In 19 patients, liver
metastases were present, which were confirmed by histopathology (n = 12), 18FDG-PET (n = 6), or surgical inspection
(n = 1). Gd-enhanced MRI with DWI showed metastases in 16/19 patients (24%), which resulted in a sensitivity of 84%
(95% CI 60–97%). Contrast-enhanced MRI showed 156 and DWI 397 metastases (p = 0.051), and 339 were particularly
small (\ 5 mm).
Conclusions In this study, Gd-enhanced MRI with DWI detected synchronous liver metastases in 24% of patients with
potentially resectable pancreatic cancer on CECT with a sensitivity of 84%. Diffusion-weighted MRI showed a greater
number of metastases than any other sequence, particularly small metastases (\ 5 mm).
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Introduction
Pancreatic cancer is one of the most lethal forms of cancer
with a 5-year relative survival rate of 6% reported by the
American Cancer Society [1]. Total deaths due to pancre-
atic cancer are increasing dramatically and expected to
become the second leading cause of cancer-related deaths
before 2030 [2, 3]. Surgery of localized pancreatic cancer
offers the only realistic chance to cure. Approximately
10–20% of patients do have unexpected liver metastases,
peritoneal carcinomatosis, or locally advanced disease at
the time of surgery [4–6]. More than 50% of all liver
metastases develop in the first six months postoperatively,
even in patients with early tumor stage [7]. These findings
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suggest that liver metastases are already present at the time
of surgery, which is supported by the mathematical model
by Haeno et al., predicting that patients likely harbor
metastases at diagnosis [8]. These synchronous liver
metastases are not identified pre-operatively, as they are
too small to be detected by routine preoperative ultrasound
and contrast-enhanced CT (CECT) [9].
International guidelines advise CECT for routine diag-
nosing and staging of pancreatic cancer, whereas MRI is
mostly used for characterization of indeterminate liver
lesions [10]. CECT allows accurate assessment of the
relationship between the tumor and critical arterial and
venous structures [11]. However, the detection of subcen-
timeter metastases by CECT poses a greater challenge.
Even if subcentimeter liver lesions are identified on a
preoperative CT scan, the ability to precisely characterize
those lesions as malignant is limited [12].
Nowadays, diffusion-weighted MR imaging (DWI) is
increasingly used for hepatic imaging and has been shown
to be a valuable tool in both detection and characterization
of focal liver lesions with a sensitivity ranging from 86 to
97% and 60 to 91% for subcentimeter lesions [13–16].
Most studies have been performed for liver metastases of
colorectal cancer. There are limited studies performed in
pancreatic cancer, all concluding that additional MRI is
useful in detecting liver metastases. Most studies used 1,5T
scanners [9, 17–20]. In the 3,0T scanners, the increased
signal-to-noise ratio can be translated into a higher reso-
lution, and the improved contrast-to-noise ratio of
gadolinium-based contrast agent can both contribute to
improved lesion detection and characterization [21]. Liver-
specific contrast agent was used in the studies by Ito et al.,
Motosugi et al. and Chew et al. for the detection of liver
metastases [17, 19, 22]. In the ESGAR consensus state-
ment, gadoxetate disodium is recommended for the diag-
nosis and characterization of malignant liver lesions in
non-cirrhotic livers [23]. Aside from the associated higher
costs, the relative hepatic enhancement could be negatively
influenced by high serum bilirubin levels, which is com-
mon in patients with obstructive jaundice in pancreatic
cancer of the head [24]. In this retrospective study, we
evaluated the sensitivity of nonspecific extracellular
gadolinium contrast-enhanced MRI (Gd-enhanced MRI)
combined with DWI for synchronous liver metastases in
potentially resectable pancreatic cancer on a 3T MR
scanner.
Materials and methods
All procedures performed in studies involving human
participants were in accordance with the ethical standards
of the institutional research committee and with the 1964
Helsinki declaration and its later amendments or compa-
rable ethical standards. For this type of study formal con-
sent is not required.
Setting and participants
All patients older than 18 years with potentially
resectable pancreatic cancer without liver metastases on
CECT and additional Gd-enhanced MRI with DWI per-
formed in our hospital from January 2012 to December
2016 were eligible for inclusion. Patients were recruited
from the Radiology Information System. MRI was rou-
tinely performed in our center in all patients with poten-
tially resectable disease or indeterminate liver lesions on
CECT. Patients with locally resectable or borderline
resectable pancreatic cancer were included. Resectability
was established using criteria of the Dutch Pancreatic
Cancer Group (PREOPANC trial, DPCG 2012). Exclusion
criteria were local or systemic treatment for pancreatic
cancer prior to imaging, locally advanced pancreatic cancer
on CECT, incomplete liver imaging, and a time interval
between CT and MRI or imaging and surgery of more than
2 months. The primary outcome parameters were the
presence of liver metastases on Gd-enhanced MRI with
DWI and the sensitivity of Gd-enhanced MRI with DWI
for synchronous liver metastases. The secondary endpoint
was the number of lesions suspicious for metastases
detected by the different MRI sequences. Confirmation of
liver metastases was obtained by histopathology, 18FDG-
PET, and surgical findings. Explorative surgery was per-
formed in all patients with (borderline) resectable tumors
without histopathological proof or 18FDG-PET confirma-
tion of metastases. Demographic characteristics were col-
lected from the electronic medical records. Survival rates
were obtained from the general practitioners in October
2015 and were updated in January 2018 from data in the
electronic medical records.
CT technique
CECT was performed in different hospitals and produced
at different models of 16- and 64-row multidetector CT
scanners. Only high-quality datasets with image acquisition
in the portal-venous phase and slice thickness of 3–5 mm
were included for analysis.
MRI technique
All MR imaging of the abdomen was performed in our
academic tertiary referral center on a 3.0 Tesla system
(Magnetom Skyra, Siemens Healthcare, Erlangen, Ger-
many). The imaging protocol is displayed in Table 1. The
protocol consisted of a T1-weighted axial in- and opposed
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phase gradient-echo VIBE, a half Fourier acquisition sin-
gle-shot turbo spin-echo (HASTE), pre- and post-contrast
T1-weighted 3D gradient-echo VIBE, and a respiratory
triggered single-shot spin-echo echoplanar DWI in the
transverse plane with monopolar diffusion gradients along
three orthogonal directions with b-values of 0/50, 500, and
800 s/mm2, using d = 10.1 ms and D = 33.5 ms. Fifteen
ml of gadoterate meglumine 0.5 mmol/mL (Dotarem,
Guerbet, Villepinte, France) was injected in an antecubital
vein at 2.5 ml/s with a saline flush (NaCl 0.9%) of 20 ml at
2.5 ml/s using a pump injector (Optistar Elite, Mallinck-
rodt, Dublin, Ireland). MR cholangiopancreatographic
images were also obtained; these images were not used in
this study.
Image interpretation
MR images were consecutively reviewed by a radiologist
(JH) with 14 years of experience in abdominal and pan-
creas imaging, on a commercial PACS workstation (Impax,
Agfa Healthcare, Belgium). The observer was blinded to
all clinical information, pathology reports, and the original
radiology report, aside from the diagnosis of pancreatic
cancer. In both modalities, liver lesions were scored using a
3-point scale: 1-benign, 2-indeterminate, 3-malignant (i.e.,
metastasis). Number, size, location, and imaging charac-
teristics and the presumed diagnosis of the lesion were
noted. Benign lesions were diagnosed using established
imaging criteria [25–27]. On CECT, hypodense lesions that
show typical features of a simple cyst (fluid attenuation
measurements, round-oval, well-defined borders, no con-
trast enhancement), a hemangioma (localization next to
vessels, peripheral nodular enhancement, centripetal fill-
in), or focal fatty infiltration (geographic hypodense area,
angular margins, typical location) are classified as benign
lesions. Indeterminate liver lesions on CECT included
hypodense liver lesions that were too small to be charac-
terized. Metastases are hypodense lesions with rim
enhancement. On MRI, metastases of pancreatic cancer are
typically of moderately high to isointense signal intensity
on T2W-images and mildly hypointense to isointense on
T1W-images. Metastases can either be hypo- or hyper-
vascular, and show homogeneous or peripheral enhance-
ment (ring or wedge-shaped) in the arterial phase,
homogeneous enhancement or peripheral enhancement
with complete or incomplete centripetal progression in the
portal-venous and interstitial phase [28]. On DWI, a lesion
was classified as malignant (i.e., metastasis) when it was
(moderately) hyperintense at b = 0/50 s/mm2 and remained
hyperintense at the highest b = 800 s/mm2 and a lesion was
considered benign when it was hyperintense at b = 0/50 s/
mm2 and showed a substantial decrease in signal intensity
at higher b-values (b = 500 and 800 s/mm2). If none of the
criteria were met, a lesion was classified as indeterminate.
For the analysis, indeterminate lesions were classified as
benign, as in clinical practice indeterminate lesions that
cannot be further classified will be regarded as benign
unless proven otherwise by biopsy. Whenever more than
ten malignant lesions (i.e., metastasis) per slice were pre-
sent, the number of malignant lesions per slice was esti-
mated in dozens.
Statistical methods
All data were processed using SPSS software (version 20,
SPSS, Chicago, IL). The sensitivity of Gd-enhanced MRI
with DWI was calculated with a 95% confidence interval
(CI). ANOVA test was performed to determine the dif-
ferences between the group with liver metastases and the
group without liver metastases. Paired samples t test was
used to determine the difference between contrast-en-
hanced MRI and DWI regarding detection of malignant
Table 1 MR imaging parameters
Parameter T1-weighted imaging in-
and opposed phase (VIBE)
T2-weighted imaging (HASTE) T1-weighted imaging
(VIBE) pre- and post-contrast
Diffusion-weighted
imaging (SPAIR)
Plane Axial Axial Coronal Axial Coronal Axial
Section thickness (mm) 3 5 3 1.5 5
Intersection gap (mm) 0 0.5 0 0 1
Repetition time (msec) 4.35 1600 1400 4.34 2.92 [ 2100
Echo time (msec) 2.45–1.33 95 87 1.89 1.05 71
Flip angle (degree) 9 90/160 90/180 9 11 90/180
Field of view (cm) 30 35 30 30 38
Matrix 320 9 195 320 9 256 320 9 195 2569 192 9 156
Bandwidth (Hz/pix) 975 710/710 445 650 1736
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lesions. The differences between various MRI sequences
regarding lesion detection were compared using the
Friedman test. Post hoc analysis with Wilcoxon signed-
rank tests was conducted with a Bonferroni correction
applied. Survival analysis was performed using Kaplan–
Meier curves with the day of diagnosis on imaging as entry
date and log-rank test to test for statistical significance. A
p value of less than 0.05 was considered statistically
significant.
Results
Patients
Sixty-six consecutive patients (median age 65 years, range
36–82 years) out of 93 patients with potentially
resectable pancreatic cancer were eligible for inclusion.
Twenty-seven patients were excluded for the following
reasons: no confirmation of the presence or absence of
malignant lesions (n = 4), local or systemic treatment prior
to imaging (n = 3), artifacts or incomplete liver imaging
(n = 8), and a time interval between imaging or imaging
and surgery of more than two months (n = 12). Nineteen
(29%) patients were diagnosed with liver metastases.
Altogether 32 out of 47 patients without liver metastases
underwent resection of the tumor. In the remaining 15
patients, the tumor was unexpectedly locally advanced
(n = 12), metastasized intraperitoneally (n = 2), or the
patient was too weak for surgery (n = 1). There was a
significant difference in the survival between patients with
liver metastases and without liver metastases
(v2(2) = 28.354, p = 0.000). Descriptives of included
patients are described in Table 2.
Confirmation of findings
Confirmation of liver metastases was obtained by
histopathology in twelve patients; only in two cases
transabdominal ultrasound with biopsy was successful. In
the remaining patients, histopathology was obtained intra-
operatively (n = 9) or by autopsy (n = 1). In six patients
without histological proof, preoperative 18FDG-PET
showed avid lesions in the liver, suggestive of liver
Table 2 Descriptives
Liver metastases 19 (29%) No liver metastases 47
(71%)
Total population 66 (100%) p value
Gender
Men 13 (68%) 29 (62%) 42 (64%)
Women 6 (32%) 18 (38%) 24 (36%)
Age (years) Median 64 (50–81) Median 66 (36–82) Median 65 (36–82) 0.828
Primary tumor location
Head 15 (79%) 37 (79%) 52 (79%)
Body/tail 2 (11%) 7 (15%) 10 (15%)
Both 1 (5%) 3 (6%) 4 (6%)
Ca19.9 Median 430 (0–5297)
(n = 16)
Median 155 (1–7400)
(n = 42)
Median 191 (0–7400)
(n = 58)
0.044
Tumor stage
I – – –
II – 27 (57%) 27 (41%)
III – 17 (36%) 27 (26%)
IV 19 (100%) 3 (6%) 27 (33%)
Treatment
Curative resection – 32 (68%) 32 (48%)
Palliative bypass 7 (37%) 6 (13%) 13 (20%)
Explorative laparotomy 3 (16%) 5 (11%) 8 (12%)
Supportive care or palliative
chemotherapy
9 (47%) 4 (9%) 13 (20%)
Survival (weeks) Median 18 ± 1.9 Median 60 ± 8.1 Median 47 ± 3.0 0.000
Out of the included 66 patients, 19 patients had confirmed synchronous liver metastases. In this table, the groups with and without liver
metastases and the total study population are depicted. The number of patients and the corresponding percentages, the median and corresponding
ranges are reported. The survival is displayed in weeks, with corresponding standard errors
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metastases. In one patient multiple liver metastases were
confirmed by intraoperative inspection and palpation of the
liver and peritoneal metastases were histologically proven.
The absence of liver metastases in the remaining 46
patients was confirmed intraoperatively by inspection and
palpation of the liver (n = 43) and 18FDG-PET (n = 4).
The mean time interval between CECT and Gd-enhanced
MRI with DWI was 15 days (SD 12 days) and 26 days (SD
14 days) between Gd-enhanced MRI with DWI and
surgery.
Lesion analysis
Gd-enhanced MRI with DWI detected malignant lesions in
16 out of 19 patients with liver metastases. The sensitivity
of Gd-enhanced MRI with DWI was 84% (95% CI
60–97%). The positive predictive value was 94% (95% CI
69–99%), and the negative predictive value was 94% (95%
CI 85–98%). There was one false positive on a per-patient
basis, in this patient one liver lesion with perilesional ring
enhancement and persistent high signal intensity on DWI
was characterized as malignant on Gd-enhanced MRI with
DWI. There was no evidence of liver metastases during
surgery and follow-up CECT after 1 year. There were three
false negatives on a per-patient basis. In the first case, one
indeterminate lesion in liver segment six on CECT was
characterized as benign on Gd-enhanced MRI with DWI.
However, intraoperative biopsy-proven metastasis in seg-
ment two was not detected on MRI. In the second case,
there were neither liver lesions on CECT nor Gd-enhanced
MRI with DWI. In the last case, one lesion was indeter-
minate on Gd-enhanced MRI with DWI, yet showed high
uptake on preoperative 18FDG-PET and thus was classified
as metastasis.
In the negative-on-CT group, the per-patient prevalence
of liver metastases was 20% (9/44). MRI was of additional
value in 16% (7/44). In the indeterminate-on-CT group, the
per-patient prevalence of liver metastases was 45% (10/
22). MRI was of additional value in 90% of the patients
(20/22).
On a per lesion basis, Gd-enhanced MRI with DWI
detected 397 malignant lesions in 16 out of 19 patients with
liver metastases. Contrast-enhanced MRI detected 156
malignant lesions, whereas DWI detected 397 malignant
lesions (p = 0.051). In three patients, 20 to 50 malignant
lesions were detected only by DWI. In one patient, even
more than 100 malignant lesions were visible only on DWI
(Fig. 1). Table 3 summarizes the detection rate of malig-
nant lesions in the different sequences of Gd-enhanced
MRI with DWI. There was a statistically significant dif-
ference in the number of malignant lesions detected by
T2W-HASTE, T1W-VIBE precontrast, arterial phase,
portal-venous phase, and DWI (v2(2) = 32.861,
p = 0.000). Post hoc analysis with Wilcoxon signed-rank
tests was conducted with a Bonferroni correction applied,
resulting in a statistically significant difference with a p
value of 0.005. DWI detected significantly more metastases
compared to T2W-HASTE (Z = - 3.181, p = 0.001),
T1W-VIBE precontrast (Z = - 3.183, p = 0.001), arterial
phase (Z = - 2.943, p = 0.003), and portal-venous phase
(Z = - 3.063, p = 0.002). Figures 2, 3, and 4 show
examples of three different patterns of liver metastases of
pancreatic cancer on Gd-enhanced MRI with DWI.
Ninety-five percent of all liver metastases detected on
Gd-enhanced MRI with DWI were subcentimeter lesions:
85% B 5 mm, 10% 6–10 mm, and 5%[ 10 mm. Nine
patients (47%) had oligometastatic liver disease (i.e., B 5
liver metastases [29]) and eleven patients had poly-
metastatic liver disease.
Discussion
In this study, liver metastases were accurately diagnosed by
Gd-enhanced MRI with DWI in 16 out of 66 (24%)
patients initially diagnosed with potentially
resectable pancreatic cancer on CECT. Adding a diffusion-
weighted MRI to the contrast-enhanced MRI increased the
number of detected metastases from 156 to 397. The
combination of contrast-enhanced MRI and diffusion-
weighted MRI yielded a high detection rate in previous
studies, particularly in small metastases [30]. Metastases of
pancreatic cancer are mostly small and multiple, which is
consistent with the study by Danet et al. [28], subcen-
timeter lesions comprising 95% of all lesions. DWI seems
particularly useful in the estimation of the metastatic load
with the detection of metastases that are smaller than
5 mm.
The prevalence of liver metastases in this study was
relatively high, 29%. The reported prevalence of liver
metastases in the previous studies varies from 4.9% to 30%
[9, 17–20, 22]. Patients with borderline resectable tumors
and patients with indeterminate liver lesions were included,
with a higher probability of having liver metastases.
Additionally, on Gd-enhanced MRI there were metastases
with a hypervascular enhancement pattern. A CECT with
only porto-venous phase might have decreased the detec-
tion of these hypervascular metastases and overall the
ability to characterize focal liver lesions on CECT. These
factors might attribute to the higher additional value of
MRI in this study as compared to the previous studies. The
sensitivity of combined contrast-enhanced and diffusion-
weighted MRI was 84%, which was comparable to other
studies with sensitivities ranging from 73 to 100%
[9, 17, 18, 22]. Given the aggressiveness of pancreatic
cancer and its tendency for rapid metastatic spread,
1760 Abdominal Radiology (2019) 44:1756–1765
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differences in sensitivity might be caused by differences in
the time interval between Gd-enhanced MRI with DWI and
the reference standard. The mean time interval in this study
between CECT and Gd-enhanced MRI with DWI was
15 days and 26 days between Gd-enhanced MRI with DWI
and surgery. A time interval of less than 20–25 days
between imaging and any planned definitive therapy seems
appropriate to grant accurate staging [4, 5, 31, 32].
Observer bias might have influenced the results of the
study in favor of Gd-enhanced MRI with DWI, as only one
observer re-evaluated the images, although in routine
clinical practice images are also viewed by one observer,
and the reported interobserver agreement for focal liver
lesions in previous studies was good to excellent
[15, 17, 18, 33–35].
A major problem was histopathological confirmation of
the findings on Gd-enhanced MRI with DWI, as biopsy of
all liver lesions is not possible and unethical in a living
patient. Therefore, determining diagnostic accuracy on a
per lesion basis is nearly impossible. Moreover, in our
bFig. 1 A 64-year-old male patient with borderline resectable pancre-
atic cancer on CECT and indeterminate liver lesions. The lesions
were characterized as liver metastases by Gd-enhanced MRI. DWI
additionally showed[ 100 metastases. The time interval between CT
and MRI was 11 days. In this patient, there was a large discrepancy
between CECT and Gd-enhanced MRI and DWI. Within 4 weeks
after initial diagnosis, the patient died of cholangitis septicemia. An
autopsy was performed and confirmed MRI findings of more than 100
liver metastases. CECT (a) shows multiple hypodense liver lesions
too small to characterize. These lesions show moderately high signal
intensity on T2W-HASTE (b), and post-contrast T1W-VIBE portal-
venous phase (c) shows rim enhancement. Diffusion-weighted MRI
shows multiple lesions (white arrows) with a high signal intensity that
remain hyperintense on the high b-value b = 800 s/mm2 (d). The
autopsy confirmed there were more than 100 liver metastases (E&F)
Table 3 Number of malignant
lesions on different sequences
of Gd-enhanced MRI with DWI
Sequence T2W-MRI T1W-MRI precontrast T1W-MRI arterial T1W-MRI portal-venous DWI
B 5 mm 13 9 100 90 339
6–10 mm 30 27 32 30 38
[ 10 mm 20 18 20 20 20
Total 63 54 152 140 397
The number of suspected liver metastases on various sequences of Gd-enhanced MRI with DWI in patients
with liver metastases
Fig. 2 A 70-year-old female patient with borderline resectable pan-
creatic cancer with three indeterminate liver lesions on CECT. Seven
lesions were characterized as liver metastases by Gd-enhanced MRI
with DWI. Liver metastases were confirmed by intraoperative
inspection and palpation of the liver. a–e Subcapsular hypervascular
lesion in liver segment six (arrow). Near isointense on T2W-HASTE
(a), near isointense on the T1W-VIBE precontrast images (b),
hyperintense with wedge-shaped enhancement in the arterial phase
(c), near isointense in the portal-venous phase (d). Persistent high
signal intensity on DWI (b = 800 s/mm2) (e)
Fig. 3 This is the same patient as the patient in Fig. 2. a–e A
malignant lesion with arterial perilesional ring enhancement with
incomplete centripetal progression in liver segment eight (arrow).
Moderately high on T2W-HASTE (a). Hypointense on T1W-VIBE
precontrast (b), perilesional ring enhancement in the arterial phase
with hypointense center (c), which remains hypointense on the portal-
venous phase (d). Persistent high signal intensity on DWI (b = 800 s/
mm2) (e)
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experience not all lesions on MRI are visible using either
transabdominal or intraoperative ultrasound, therefore
determining diagnostic accuracy on a per-patient basis
remains challenging. In future clinical practice, MRI-gui-
ded biopsy with follow-up imaging could become an
alternative strategy. In this study, there was one false
positive on a per-patient basis; in previous studies false
positives were also reported [17, 20, 22]. Therefore, at this
moment we cannot deny patients surgery without
histopathological proof of the radiological malignant liver
lesions.
The increased safety of operations has led to more
extensive local pancreas resections with venous and arterial
reconstructions. Also, more effective chemotherapy pro-
tocols have been introduced, including combination ther-
apies such as FOLFIRINOX. After neoadjuvant therapy in
patients with borderline resectable pancreatic cancer or
even locally advanced pancreatic cancer, secondary
resection proved feasible with acceptable morbidity and
survival rates [36]. Although still controversial, small
studies and case reports have described select patients with
oligometastatic hepatic metastases undergoing curative
resection of the pancreas and the synchronous hepatic
metastases [37, 38]. To benefit from these developments,
adequate staging is a prerequisite and information on size,
number, and distribution of liver metastases are of the
utmost importance. Improved detection of liver metastases
could reduce futile resection of the tumor with its associ-
ated morbidity and mortality in these patients with a
markedly reduced life expectancy. Moreover, it offers the
possibility to start palliative systemic chemotherapy earlier
as there is no recovery period from the operation. Also, it
can reduce palliative bypass surgery as the prognosis for
metastatic disease is even worse than for locally advanced
disease [39]. Patients with obstructive symptoms can suc-
cessfully be treated with endoscopically placed biliary and
enteric stents, which is a safe, efficacious, and cost-effec-
tive procedure with good clinical outcome [40]. Finally,
improved detection of liver metastases during monitoring
of (neo)adjuvant treatment could lead to a change in
therapeutic strategy.
The retrospective nature of this study prevents a reliable
calculation of the specificity, positive and negative pre-
dictive value of Gd-enhanced MRI with DWI versus
CECT. Therefore, we started a large international multi-
center prospective study to validate these results and to
determine the diagnostic accuracy, implications for clinical
decision making, and cost-effectiveness of Gd-enhanced
MRI with DWI.
This study showed that Gd-enhanced MRI with DWI
detected synchronous liver metastases in 24% of patients
with potentially resectable pancreatic cancer on CECT with
a sensitivity of 84%. Contrast-enhanced MRI showed 156
malignant lesions versus 397 malignant lesions with DWI,
most of which were particularly small (\ 5 mm).
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